hATTR clinical trials at UCSF

1 research study open to eligible people

hATTR refers to hereditary transthyretin amyloidosis, a rare condition caused by protein deposits. UCSF is gathering information from hATTR patients to watch the natural progress of the disease. This research aims to find trends that could lead to better treatments down the line.

Showing trials for

  • Patients With Transthyretin (ATTR) Amyloidosis

    open to eligible people ages 18-130

    The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

    San Francisco, California and other locations

Last updated: